These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21546632)

  • 1. Efforts to support the development of fusidic acid in the United States.
    Fernandes P; Pereira D
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S542-6. PubMed ID: 21546632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
    Jones RN; Mendes RE; Sader HS; Castanheira M
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Yu XH; Song XJ; Cai Y; Liang BB; Lin DF; Wang R
    J Antibiot (Tokyo); 2010 Nov; 63(11):657-9. PubMed ID: 20877368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction: fusidic acid enters the United States.
    Moellering RC; Corey GR; Grayson ML
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
    [No Abstract]   [Full Text] [Related]  

  • 5. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP; Grayson ML
    Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.
    Lemaire S; Van Bambeke F; Pierard D; Appelbaum PC; Tulkens PM
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S493-503. PubMed ID: 21546626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
    Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
    Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.
    Tsuji BT; Okusanya OO; Bulitta JB; Forrest A; Bhavnani SM; Fernandez PB; Ambrose PG
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S513-9. PubMed ID: 21546628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusidic acid resistance in Staphylococcus aureus isolates.
    Brown EM; Thomas P
    Lancet; 2002 Mar; 359(9308):803. PubMed ID: 11888633
    [No Abstract]   [Full Text] [Related]  

  • 10. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data.
    Rennie RP
    J Cutan Med Surg; 2006; 10(6):277-80. PubMed ID: 17241597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: treatment of chronic osteomyelitis.
    Wolfe CR
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S538-41. PubMed ID: 21546631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
    Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
    Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-acquired methicillin-resistant Staphylococcus aureus infections in children.
    Kaplan SL
    Semin Pediatr Infect Dis; 2006 Jul; 17(3):113-9. PubMed ID: 16934705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing resistance to fusidic acid among clinical isolates of MRSA.
    Wang JT; Huang IW; Chang SC; Tan MC; Lai JF; Chen PY; Lauderdale TL
    J Antimicrob Chemother; 2017 Feb; 72(2):616-618. PubMed ID: 27733516
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety record of fusidic acid in non-US markets: a focus on skin infections.
    Kraus CN; Burnstead BW
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S527-37. PubMed ID: 21546630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study.
    Mason BW; Howard AJ
    Int J Antimicrob Agents; 2004 Mar; 23(3):300-3. PubMed ID: 15164973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro sensitivity of methicillin-resistant Staphylococcus aureus to fusidic acid and trimethoprim-sulfamethoxazole].
    Memikoğlu KO; Bayar B; Kurt O; Cokça F
    Mikrobiyol Bul; 2002 Apr; 36(2):141-5. PubMed ID: 12652865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility patterns of methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus corneal isolates to antibiotics.
    Elsahn AF; Yildiz EH; Jungkind DL; Abdalla YF; Erdurmus M; Cremona FA; Rapuano CJ; Hammersmith KM; Cohen EJ
    Cornea; 2010 Oct; 29(10):1131-5. PubMed ID: 20595899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing rate of detection of fusidic acid resistance in methicillin-resistant Staphylococcus aureus isolated from clinical samples in Malaysia.
    Alreshidi MA; Mariana NS
    Med J Malaysia; 2011 Aug; 66(3):276. PubMed ID: 22111461
    [No Abstract]   [Full Text] [Related]  

  • 20. First vanguard anti-MRSA agent approved.
    Fox JL
    Nat Biotechnol; 2014 Jul; 32(7):603. PubMed ID: 25004211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.